anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As the burden of type 2 diabetes (T2D) continues to escalate globally, there is a growing need for novel, less-invasive biomarkers capable of early diabetes detection and monitoring of disease progression. Liquid biopsy, recognized for its minimally invasive nature, is increasingly being applied beyond oncology, and nevertheless shows its potential when the collection of the tissue biopsy is not possible. This diagnostic approach involves utilizing liquid biopsy markers such as cell-free nucleic acids, extracellular vesicles, and diverse metabolites for the molecular diagnosis of T2D and its related complications. In this context, we thoroughly examine recent developments in T2D liquid biopsy research. Additionally, we discuss the primary challenges and future prospects of employing liquid biopsy in the management of T2D. Prognosis, diagnosis and monitoring of T2D through liquid biopsy could be a game-changing technique for personalized diabetes management.
PURPOSE:To detect easily and accurately the transforming gross factor (TGF) created by the cancer cells of human and rodents from the presence or absence of flucculation by adding a reagent contg. the solid particles on the surface of which an antibody for the TGF is deposited to the urine, etc. to be tested. CONSTITUTION:A rabbit or the like is immunized by the human TGF active fraction refined from the urine of a cancer patient by subjecting the same to a treatment such as dialysis, gel filtration or the like, by which a serum contg. the antihuman TGF is obtd. An IgG fraction is drawn from such serum and is sensitized with latex particles of polyestyrene, etc., by which particles of 0.05-10mu grain size deposited thereon with the human TGF antibody are obtd. A buffer of 7-9pH contg. 0.5-2wt% such particles, 0.01-0.2wt% protein such as albumin of a cattle serum, and 0.02-0.2wt% sodium azide is used as a reagent for assaying TGF. An amino acid and polyol are added to such reagent and the reagent can be stably preserved in the form of a freeze-dried reagent. The reagent is added to the urine, etc. to be tested and the presence of absence of flocculation therein is observed or is measured with absorbancy. The assay of TGF, that is, the diagnosis of the cancer is thus easily and exactly accomplished.
BACKGROUND: The effect of time to surgery after completion of neoadjuvant chemotherapy and outcomes in breast cancer patients remains poorly defined. Acceptable time to surgery has frequently been arbitrarily defined as between four to eight weeks. This study aims to ascertain if time to surgery after completion of neoadjuvant chemotherapy impacts disease-free survival (DFS) and overall survival (OS).
MATERIALS AND METHODS: This single-institution retrospective study included patients who underwent neoadjuvant therapy and subsequent surgery from 2006 to 2017. Demographic, clinicopathological factors, and surgical data from 259 patients were analyzed. 105 patients received surgery within 28 days (group 1). 128 patients received surgery within 29-56 days (group 2), and 26 patients received surgery after 57 days or more (group 3). DFS and OS among the three groups were compared.
RESULTS: Age, race, pre-chemotherapy stage, tumor type, grade, hormone receptor status, Her2 status, focality, lymphovascular invasion, radiological response to chemotherapy, type of surgery, pathological response to chemotherapy, and receipt of adjuvant radiotherapy were not significantly different between the three groups. Only receipt of adjuvant chemotherapy was statistically significant (p = 0.0230). DFS and OS between the three groups were not found to be significantly different (p = 0.520 and p = 0.369, respectively).
CONCLUSION: Time to surgery after completion of neoadjuvant chemotherapy did not appear to affect recurrence or survival outcomes. Findings from this study may allow more flexibility and reduce the burden of scheduling patients for surgery within the usual four-to-eight-week window in centers with resource and scheduling constraints.
Community dwelling adults aged 18 years or older with no diagnosis of mTBI/concussion within the last 6 months. Population will be matched to the concussion population within the age, gender, and height range of the concussion population.
The ketogenic composition includes a racemic mixture of R-and S-beta-hydroxybutyrate and a racemic mixture of R-and S-beta-hydroxybutyrate. The compositions contain the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved, and also contain an equivalent amount of the S-enantiomer to provide replacement benefits. R-and S- β -hydroxybutanoic acid are absorbed and utilized by the body more quickly than salts or esters, enhance taste, and reduce the need to include citric acid or other edible acids. R-and S-beta-hydroxybutyrate are more slowly absorbed and utilized by the body and may provide one or more electrolytes. The ketogenic composition may comprise a dietetically or pharmaceutically acceptable carrier and a racemic mixture of R-and S-beta-hydroxybutyrate and acid. The composition contains less than 100 mole equivalents of total R, S-beta-hydroxybutyrate and greater than 0 mole equivalents of R, S-beta-hydroxybutyrate.
Diabetic foot ulcers are primarily caused by poor circulation, high blood sugar (hyperglycemia), nerve damage, and foot irritation or injury. These factors, particularly poor circulation and high blood sugar, often hinder the healing process of ulcers. TWB-103 is a combination of TWB-102 cells (human fetal dermal fibroblasts) and TWB-103 hydrogel. The objective of this study was to determine whether the application of TWB-103 on diabetic ulcer wounds could accelerate the healing process in subjects with diabetic lower limb ulcers that had not shown signs of healing for at least four weeks. The study was designed as a Phase I/II, single-arm trial, with a planned enrollment of 10 subjects. These subjects would receive up to 12 weekly applications of TWB-103, and the study would evaluate both the safety and efficacy of the treatment.
Anti-Caries Varnish. The active ingredients are 10% (w/v) Povidone-Iodine and 5% (w/v) Sodium Fluoride CAS.
Sexually transmitted infections (STI) or sexually transmitted diseases (STD) can be caused by bacteria, viruses, fungi, protozoa and arthropods. The most frequent bacterial STIs include Chlamydia infections, syphilis and gonorrhea; viral STIs include herpes genitalis (herpes simplex virus 1 and 2), human papillomavirus (HPV) and human immunodeficiency virus (HIV). An empathetic medical history taking in cases of a clinical suspicion can provide important information for adequate diagnostics. When an STI is detected, a complete screening for other STIs should be carried out. The STIs result in a wide variety of symptoms and it is often difficult to make a clear diagnosis to a certain pathogen based on the clinical symptoms. To avoid reinfections, it is recommended to also test recent sexual partners. For certain pathogens highly effective postexposure prophylaxis or preventive vaccinations are available.
FIELD: medicine, pharmacy. SUBSTANCE: composition has at least one active component, 0.5-60 weight% of at least one vehicle and 5-50 weight% of at least one water-soluble at physiological values pH alkalinizing agent. Vehicle is taken among inert matrices, hydrophilic matrices, their mixtures and lipid matrices with exception for mixtures containing polyacrylic acid and at least one hydrophilic matrix of cellulose type. Alkalinizing agent is taken among alkaline or alkaline-earth metal hydroxides, carbonates, hydrocarbonates and phosphates, sodium borate and organic acid basic salts. The second variant of composition is made as two layers being at least one layer has an active substance and vehicles and provides immediate release of this active substance after its administration. At least one the second layer has composition described above and provides the sustained-release of the same or the second active substance. By the first variant method of the composition preparing involves preparing the homogeneous mixture of indicated components, granulation of mixture and its tableting. By the second variant method of the composition preparing involves separate preparing homogeneous mixtures of layer components, their following tableting in device for multilayer tableting. Invention provide to develop medicinal forms with sustained-release of active substances in the case of administration of substances by small daily doses, preferably as a single daily dose. Therapeutic effect of substances is evident for prolonged time, for 12 h, not less. Invention can be used for preparing preparations for oral administration. EFFECT: improved properties of composition, improved method of preparing. 10 cl, 5 dwg, 27 tbl
Participants will be administered test product (containing 500 mg paracetamol). Two tablets will be taken orally once with 200 mL of water.
* Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1), and Drug Interactions (7.1)].
  * The use of benzodiazepines, including SYMPAZAN, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing SYMPAZAN and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction [see Warnings and Precautions (5.2)].
  * The continued use of benzodiazepines, including SYMPAZAN, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of SYMPAZAN after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue SYMPAZAN or reduce the dosage [see Dosage and Administration (2.2) and Warnings and Precautions (5.3)].
PURPOSE:To obtain the subject new compound having excellent antiviral activity, low in cytotoxicity, resistant to adenosine deaminase, useful as a highly safe antiviral agent. CONSTITUTION:A compound of formula I (A is CH or N), e.g. (2S,3S,4R)-2,3- isopropylideneoxy-4-hydroxy-4-ethoxycarbonylmethyl-5-cyclopentene. The compound of formula I can be obtained by reaction of a cyclopentene derivative of formula II (R1-R3 are each protecting group for OH; X is electron-attractive eliminable group) with (B) an adenine derivative of formula III (R4 is H or amino-protecting group) in an inert solvent (e.g. DMF) at room temperature to elevated temperatures. The compound of formula I is highly large in chemotherapeutic index defined as the ratio of minimum cytotoxic concentration to viral proliferation-inhibitory concentration and also large in the difference between the concentration giving antiviral activity and that giving cytotoxicity, thus being a safe medicine.
Ulipristal acetate 60mg orally x 1 dose, washout cycle, and then in next menstrual cycle 30mg orally x 1 dose. Timing of dosage depends on follicle measurements.
The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes.  Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. Methods of using, inter alia, CPHPC, the 4,6-pyruvate acetyl of beta-D-galactopyranose, ethanolamines, high EEO  agarose, IL-4, and IL-13, and anti-SAP antibodies and fragments thereof to increase monocyte differentiation into fibrocytes are provided. These methods are useful in a variety of applications, including wound healing. Wound dressings are also provided. Finally, the invention includes assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects.
Patients received a 4-week treatment program (12 treatment sessions, three times a week). Patients received the conservative treatment protocol comprised of ultrasound, hot pack application, and exercises.
BACKGROUND: Iatrogenic colonoscopy perforation (ICP) is a rare but most serious complication during colonoscopy investigation. However, endoscopic closure plays an important role in the dealing with ICP with the development of endoscopic techniques presently, there are still some portion of patients transferred to surgery.
METHODS: Once a perforation was detected, endoclips were used to closed the defect of the colon. Then a colonic TET was planted inside the colon. The terminal end of the TET was put proximally to or near the location of the perforation. Then gas and fluid was sucked out through the TET with a syringe every 4 h.
RESULTS: Three cases were treated with endoclip closure and colonic TET drainage. Case 1 was caused by urgent immediate perforation during routine colonoscopy, case 2 was delayed perforation after snare resection, and case 3 was ESD-related perforation. All patients got healed, no one transferred to surgery.
CONCLUSIONS: A combination of endoclip closure and colonic TET drainage might be an easy and potential method in the dealing with different types of ICP. This study may offer a novel paradigm for addressing endoscopy-related intestinal perforations.
BACKGROUND: Recurrent genetic abnormalities affecting pivotal signaling pathways are the hallmark of childhood acute lymphoblastic leukemia (ALL). The identification of these aberrations remains clinically important. Therefore, we sought to determine the cytogenetic profile and the mutational status of TP53 and RAS genes among Moroccan childhood cases of ALL.
METHODS: In total, 35 patients with childhood ALL were enrolled in the study. The diagnosis and treatment were established in the Pediatric Hematology and Oncology Center at the Children's Hospital of Rabat. Chromosome banding analysis and fluorescence in situ hybridization were used to detect genetic aberrations. Blood samples were screened for TP53 and RAS mutations using Sanger sequencing.
RESULTS: Of the 35 cases, 30 were B-lineage ALL (85.7 %). Moreover, a male predominance was observed. Cytogenetic analysis revealed chromosomal anomalies in 27 cases (77.1 %). The most frequent aberrations were high hyperdiploidy and BCR/ABL rearrangement. Interestingly, we found the rare t(15;16) and the t(8;14), which are uncommon translocations in pediatric B-ALL. The mutational analysis revealed Pro72Arg (rs1042522:C > G) and Arg213Arg (rs1800372:A > G) in TP53. In correlation with cytogenetic data, rs1042522:C > G showed a significant association with the occurrence of chromosomal translocations (p = 0.04). However, no variant was detected in NRAS and KRAS genes.
CONCLUSION: Our findings emphasize the significance of detecting chromosomal abnormalities as relevant prognostic markers. We also suggest a low occurrence of genetic variants among Moroccan children with ALL.
Investigators will randomize 15 patients into this control arm. All participants will undergo a semi-structured patient interview about how social needs impact health and self-perceptions of health at the time of enrollment and again in 6 months.
Paratracheal pressure has been recently suggested to compress and occlude the upper esophagus at the lower left paratracheal region to prevent gastric regurgitation alternative to cricoid pressure. It also prevents gastric insufflation. The aim of this randomized cross-over study was to investigate the effectiveness of paratracheal pressure on mask ventilation in obese anesthetized paralyzed patients. After the induction of anesthesia, two-handed mask ventilation was initiated in a volume-controlled mode with a tidal volume of 8 mL kg‒1 based on ideal body weight (IBW), a respiratory rate of 12 breaths min- 1, and positive end-expiratory pressure of 10 cmH2O. Expiratory tidal volume and peak inspiratory pressure were recorded alternately with or without the application of 30 Newtons (approximately 3.06 kg) paratracheal pressure during a total of 16 successive breaths over 80 s. Association of patient characteristics with the effectiveness of paratracheal pressure on mask ventilation, defined as the difference in expiratory tidal volume between the presence or absence of paratracheal pressure were evaluated. In 48 obese anesthetized paralyzed patients, expiratory tidal volume was significantly higher with the application of paratracheal pressure than without paratracheal pressure [496.8 (74.1) mL kg- 1 of IBW vs. 403.8 (58.4) mL kg- 1 of IBW, respectively; P < 0.001]. Peak inspiratory pressure was also significantly higher with the application of paratracheal pressure compared to that with no paratracheal pressure [21.4 (1.2) cmH2O vs. 18.9 (1.6) cmH2O, respectively; P < 0.001]. No significant association was observed between patient characteristics and the effectiveness of paratracheal pressure on mask ventilation. Hypoxemia did not occur in any of the patients during mask ventilation with or without paratracheal pressure. The application of paratracheal pressure significantly increased both the expiratory tidal volume and peak inspiratory pressure during face-mask ventilation with a volume-controlled mode in obese anesthetized paralyzed patients. Gastric insufflation was not evaluated in this study during mask ventilation with or without paratracheal pressure.
While there is an agreement that women at risk for abnormalities of fetal growth should have serial ultrasound examinations in the 3rd trimester, there is a lack of consensus on how frequently these exams should be done. The American College of Obstetrics and Gynecology recommend that an ultrasound to assess fetal growth be performed between 2 to 4 weeks; however, there have been no prospective or randomized trials to determine whether the optimal interval should be closer to 2 weeks or delayed to 4 weeks. Currently, only 60% of fetuses' with abnormal growth are detected antenatally. There is equipoise of whether ultrasound every 2 versus 4 weeks improves the detection and subsequent newborn outcomes or merely leads to an increase in false positives and unnecessary interventions. It has been proposed, that if delivery occurs within 2 weeks of the ultrasound, the antenatal detection of abnormal growth may be more accurate and hence more likely to improve outcomes. Conversely, a shorter interval may result in confusion as to whether there is actual change in growth or merely variation in the measurement technique itself. Moreover, with the cost of ultrasound averaging approximately $200 per examination, the interval between ultrasounds can have major implications on public-health costs as well as the interventions that subsequently follow if an abnormality is detected.

The purpose of this randomized controlled trial is to compare the frequency of the diagnosis of fetal growth abnormalities when ultrasound assessment is performed at 2 versus 4 week intervals.
Methods, apparatus, and systems for pairing a patient's mobile device with a medical device are disclosed. The methods, systems, and apparatus use a server that is securely connected to a medical device to manage a pairing process. The secure connection between the server and the medical device is used to transmit a certificate in addition to a phone number of a patient's mobile device. The server also transmits a pairing code to the medical device using the secure connection. The medical device displays the pairing code. A patient causes the mobile device to record the code, which is transmitted to the server to perform a congruency check by comparing the received code to the generated code. When the codes match, the server transmits a device identifier of the mobile device to the medical device, which enables the medical device to establish a secure proximity communication channel with the medical device.
<P>PROBLEM TO BE SOLVED: To provide a fusion protein especially containing RAGE polypeptide and relating to the regulation of receptor for advanced glycation endproducts (RAGE), a method for producing the fusion protein and the use of the protein for the treatment of RAGE-based disorder.  <P>SOLUTION: The invention discloses an RAGE fusion protein containing an RAGE polypeptide sequence connected to the second non-RAGE polypeptide. The RAGE fusion protein can use an interdomain linker directly connected to an RAGE polypeptide domain containing the RAGE ligand bonding site and an immunoglobulin C<SB>H</SB>2 domain. Such fusion protein can provide a specific and high affinity bond to the RAGE ligand. The invention further discloses the use of the RAGE fusion protein for the treatment of RAGE-mediated pathology.  <P>COPYRIGHT: (C)2007,JPO&INPIT
RBD is one of the representative non-motor symptoms of PD and other synucleinopathies. Patients with RBD show dream-enacting behaviors such as punching, kicking, singing, screaming, or somnambulism. These can interfere in sleep quality and increase the risk of falling down from the bed and physical injuries of both the patient and sleep partner. Therefore, qualities of life of the patient and sleep partner are negatively influenced by presence of RBD.

Clonazepam has been used for treatment of choice of RBD. It decreased RBD symptoms completely in 55-79% and partially in 11-32% of patients. However, these results are based on open-label or descriptive studies. There has been no randomized placebo controlled study that evaluated the efficacy and safety of clonazepam for treating RBD.